Economic impact of dengue illness in the Americas.
Shepard DS, Coudeville L, Halasa YA, Zambrano B, Dayan GH. · 2011
Read Economic impact of dengue illness in the Americas. by Shepard DS, Coudeville L, Halasa YA, Zambrano B, Dayan GH. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3029168.txt.
Introduction
Shepard and coauthors estimated in 2011 what dengue illness costs the Americas each year. Dengue is a mosquito spread virus that causes fever and, in severe cases, dangerous bleeding. The team combined national case counts from 2000 to 2007 with cost studies and with estimates of how many cases never get reported.
Their total came to roughly two billion dollars a year on average, though the figure swung widely between years and outbreak sizes. Even so, the count left out spending on mosquito control, so the true burden is likely higher. The authors note the cost tops that of several other viral illnesses. The numbers are meant to help governments weigh prevention programs against the losses dengue already causes.
Catalog record
| CREATOR | Shepard DS, Coudeville L, Halasa YA, Zambrano B, Dayan GH. |
|---|---|
| YEAR | 2011 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Economic Impact of Dengue Illness in the Americas By Donald S. Shepard, Laurent Coudeville, Yara A. Halasa, Betzana Zambrano, Gustavo H. Dayan Published in: The American Journal of Tropical Medicine and Hygiene DOI: 10.4269/ajtmh.2011.10-0503 ABSTRACT The growing burden of dengue in endemic countries and outbreaks in previously unaffected countries stress the need to assess the economic impact of this disease. This paper synthesizes existing studies to calculate the economic burden of dengue illness in the Americas from a societal perspective. Major data sources include national case reporting data from 2000 to 2007, prospective cost of illness studies, and analyses quantifying underreporting in national routine surveillance systems. Dengue illness in the Americas was estimated to cost $2.1 billion per year on average (in 2010 US dollars), with a range of $1–4 billion in sensitivity analyses and substantial year to year variation. The results highlight the substantial economic burden from dengue in the Americas. The burden for dengue exceeds that from other viral illnesses, such as human papillomavirus (HPV) or rotavirus. Because this study does not include some components (e.g., vector control), it may still underestimate total economic consequences of dengue. INTRODUCTION Over the past four decades, dengue disease has become recognized as the world's most important mosquito-borne viral disease, emerging in countries previously considered free of disease and reemerging in countries where the disease was once controlled.1,2 Inadequate mosquito control and increasing urbanization and air travel have placed an estimated 3 billion inhabitants of the world's tropical areas and roughly 120 million travelers at risk of dengue infection each year.2–5 Globally, the projected number of annual dengue infection cases is 50–100 million, with approximately 24,000 deaths, mainly in children, and an estimated annual burden of 750,000 disability-adjusted life years (DALYs).3,5–10 About 36 million symptomatic cases are estimated to occur annually.11 The case of the Americas is of special interest. From the 1950s to the 1970s, the Americas were a virtually dengue-free zone because of the eradication of Aedes aegypti (the principal vector of dengue in this continent) in a continent-wide vector control campaign. Combined with the campaign's interruption in the early 1970s, the acceleration of uncontrolled urbanization with its associated waste management problems in many Latin American cities contributed to the extensive distribution of Ae. aegypti and the return of dengue virus circulation.1,7,12–15 During the last two decades, all tropical areas of Central and South America, as well as most of the Caribbean, have experienced a sharp increase in the incidence of both dengue fever (DF) and dengue hemorrhagic fever (DHF): almost 3 million dengue cases were officially reported in the Americas for the period of 2001–2005 compared with 2.1 million cases for the period of 1995–1999.14,16–18 Dengue ranks fifth in the list of neglected tropical diseases in the Americas in terms of DALYs.19 However, with weak, passive surveillance systems, the true burden may be underestimated. Serological surveys suggest the occurrence of millions of dengue infections annually in the region.9,14,20–23 Additionally, epidemic dengue occurs cyclically every 3–5 years, with evidence suggesting an increase in the magnitude and severity of cases with each new epidemic.2,9,24,25 The few economic and social evaluations of dengue published to date provide empirical estimates for only one or a small number of countries, and comparisons are limited by important methodological differences.4,9,26–35 The cost of dengue has not been estimated at the scale of the American continents. Such estimates, which are available for several other vaccine-preventable diseases, are useful for developers of drugs, vaccines, insecticides, and novel insect control approaches as well as international donors and national governments to prioritize their efforts.36–39 To help address this need, this paper estimates of the economic costs and DALYs lost because of this disease in the Americas. MATERIALS AND METHODS Five major components are needed for estimating the economic and disease burden of a disease from a societal perspective: (1) the number of reported dengue cases, (2) the degree of underreporting, (3) the direct and indirect costs per case, (4) the DALY burden per case, and (5) the country's demographic information. Reported dengue cases. The number of dengue cases was obtained from the Pan American Health Organization (PAHO), the regional body of the World Health Organization (WHO) responsible for the 35 nations and 9 territories of the Americas.16 Dengue is subject to important year to year variations in incidence. To stabilize the projections, estimations reported in this paper were based on the average of DF, DHF, and fatal cases reported over the period of 2000–2007 under the PAHO case definition.18 Countries were divided into six subregions: North America (United States of America and Canada), Central America and Mexico, the Andean region (Bolivia, Colombia, Ecuador, Peru, and Venezuela), Brazil, the Southern cone (Argentina, Chile, Paraguay, and Uruguay), and the Caribbean region. Reported dengue cases (DF and DHF) are presented in Figure 1. [Figure: Number of dengue reported cases in the Americas from 2000 to 2007.] The age distribution of cases, required for the estimation of DALYs and indirect cost of deaths, was available for Brazil, Mexico, Costa Rica, El Salvador, Honduras, Colombia, and Venezuela. For other countries in these three subregions, we applied the average country proportions from each subregion. For the three subregions with no country-specific information (Caribbean region, North America, and Southern cone), the average of all seven countries with available data was used. Dengue surveillance and underreporting. Routine surveillance systems do not capture all dengue cases.20 To estimate the actual number of cases, reported cases need to be multiplied by a correction or expansion factor (EF), which represents the degree of underreporting.40 We identified five field studies in four American countries that provided sufficient information to estimate the underreporting rate (Table 1). Reporting of hospitalized cases (the severest cases) is relatively complete (range = 1.4–3.4).41–43 Reporting of milder, ambulatory cases is less complete. In a study in Nicaragua, combining all types of dengue cases, the EF ranged from 14 to 28.44 In addition to these five field studies, other authors provide estimates of underreporting. Luz and others45 recommended EFs for Brazil ranging from 1 to 10 for endemic years and from 0.3 to 10 for epidemic years using uniform distributions (central values = 5.5 and 5.15). Armien and others27 used an EF of 6 in estimating the costs of Panama's 2005 dengue epidemic. Meltzer and others35 used an EF of 10 for 0- to 15-year-old children and an EF of 27 for older children and adults in Puerto Rico. We defined two EFs per country—one (EF1) for hospitalized and fatal cases and a second (EF2) for cases managed entirely in an ambulatory setting—and applied extensive sensitivity analyses to account for the uncertainty of these estimations. In countries with empirical estimates, EFs were defined in accordance with existing data. EF1 was set at 1.6 (range = 1.4–3.0) for Brazil, 2.3 (range = 1.4–3.3) for Colombia, Panama, and Nicaragua, and 2.4 (range = 2.3–3.4) for Puerto Rico. EF2 was set at 5 (range = 2.1–10) for Brazil, 9 (range = 4.5–18) for Colombia, 20.4 (range = 16–28) for Nicaragua, 6 (range = 3–12) for Panama, and 15 (range = 10–27) for Puerto Rico. In countries without empirical estimates, we used average expansion factors of 2.3 (range = 1.4–3.3) for EF1 and